What Genetic Testing Can Tell You Before and After Diagnosis
Cancer Research
Genomic Testing
Precision Medicine
There are two types of DNA tests for prostate cancer, and most men do not know the difference. That matters because the right test depends entirely on where you are in your health journey.
Share this BLOG article
The first type, called germline testing, looks at the DNA you were born with to find out whether you carry an inherited gene change that significantly raises your lifetime risk of prostate cancer. This is a prevention tool, most useful for men with a relevant family history or before any diagnosis. (Prostate Cancer Foundation)
The second type, called tumor genomic sequencing or somatic testing, analyzes the genetic changes inside a prostate cancer tumor after a diagnosis to identify which treatments are most likely to work. This is a treatment tool.
Both are DNA tests. They answer completely different questions. This guide explains who each one applies to, and how they work together.
DNA Testing for Prostate Cancer: Key Numbers
1 in 7
Lifetime diagnosis
Men will be diagnosed with prostate cancer in their lifetime.
American Cancer Society
5–10%
Inherited cases
Of prostate cancers are caused by an inherited mutation passed down through families.
NCI
2–6x
Higher risk
Higher lifetime prostate cancer risk for men who carry a BRCA2 mutation. These cancers also tend to be more aggressive.
NCI
All men
Metastatic disease
Diagnosed with metastatic prostate cancer are recommended for germline genetic testing, regardless of family history.
NCCN
BRCA2 tumor mutations
Treatment relevance
Can predict whether a patient may respond to PARP inhibitor therapies, a targeted treatment option for metastatic prostate cancer.
NCI
DNA testing for prostate cancer serves two purposes: understanding inherited risk before a diagnosis, and guiding treatment decisions after one. Source: ACS, NCI.
Two Types of DNA Tests for Prostate Cancer, Two Different Purposes
Germline Testing: Understanding Your Inherited Risk
Germline DNA testing analyzes the DNA you inherited from your parents, which is present in every single cell of your body from birth. A germline prostate cancer test looks for inherited gene changes in genes like BRCA2, BRCA1, Lynch syndrome genes, and HOXB13 that significantly raise the lifetime risk of developing prostate cancer. (American Cancer Society)
This type of testing is relevant for:
Men with a family history of prostate cancer, especially if a relative was diagnosed before age 60 or if multiple relatives have been affected
Men who have a family member with a known BRCA mutation, whether that relative is male or female
Men whose family history includes ovarian, breast, pancreatic, or colorectal cancer in patterns that suggest a hereditary syndrome
Men who want to understand their inherited cancer risk before any symptoms or PSA changes appear
Somatic Testing: Understanding a Tumor After Diagnosis
Somatic DNA testing, also called tumor genomic sequencing, analyzes the specific gene changes that occur within the tumor itself. These are not inherited changes. They are mutations that accumulate in cancer cells over time and are specific to that tumor.
Somatic testing for prostate cancer is used to:
Identify gene changes in the tumor, such as BRCA2, ATM, CDK12, or mismatch repair genes, that may predict whether PARP inhibitors, immunotherapy, or other targeted therapies will work
Match patients to active clinical trials that target specific tumor mutations
Understand the tumor's biology to anticipate how the disease may progress
Somatic testing requires tissue from a biopsy or prostatectomy. The results apply only to the tumor. They do not provide information about inherited risk and generally do not have implications for family members.
Two DNA Tests for Prostate Cancer
Factor
Germline Test
Somatic Test
What it analyzes
Inherited DNA
The DNA you were born with, present in every cell since birth
Tumor DNA
Mutations that developed inside the prostate tumor over time
Sample needed
Cheek swab, saliva, or blood draw
Biopsy tissue from the prostate tumor
Who it’s for
Men who want to know if they carry an inherited prostate cancer risk, whether or not they have been diagnosed
Men who have already been diagnosed with prostate cancer and need to know which treatments may work best
What a positive result means
You carry an inherited mutation that significantly raises your lifetime prostate cancer risk
Targetable tumor mutation found, may predict response to a specific therapy
Does it affect family members?
Yes. All first-degree relatives, including brothers, sons, sisters, and daughters, each have a 50% chance of carrying the same mutation. Women who inherit it won’t develop prostate cancer, but they may face elevated breast or ovarian cancer risk and can pass it to their sons.
No. Mutations that develop inside a tumor are not passed on to family members
What it analyzes
Germline Test
The DNA you were born with, present in every cell since birth
Somatic Test
Mutations that developed inside the prostate tumor over time
Sample needed
Germline Test
Cheek swab, saliva, or blood draw
Somatic Test
Biopsy tissue from the prostate tumor
Who it’s for
Germline Test
Men who want to know if they carry an inherited prostate cancer risk, whether or not they have been diagnosed
Somatic Test
Men who have already been diagnosed with prostate cancer and need to know which treatments may work best
What a positive result means
Germline Test
You carry an inherited mutation that significantly raises your lifetime prostate cancer risk
Somatic Test
Targetable tumor mutation found, may predict response to a specific therapy
Does it affect family members?
Germline Test
Yes. All first-degree relatives, including brothers, sons, sisters, and daughters, each have a 50% chance of carrying the same mutation. Women who inherit it won’t develop prostate cancer, but they may face elevated breast or ovarian cancer risk and can pass it to their sons.
Somatic Test
No. Mutations that develop inside a tumor are not passed on to family members
Many men diagnosed with prostate cancer benefit from both tests — germline testing for inherited risk and family implications, somatic testing to guide treatment. They answer different questions and are not interchangeable.
Source: NCI, NCCN
Who Should Get a Germline DNA Test for Increased Prostate Cancer Risk?
Family History Signals That Warrant Testing
Germline prostate cancer DNA testing is appropriate for men who have:
A father or brother diagnosed with prostate cancer before age 60
Two or more first-degree relatives with prostate cancer at any age
A family member, male or female, with a confirmed BRCA1 or BRCA2 mutation
A family pattern of ovarian, breast, and prostate cancer across generations, which often indicates a BRCA mutation carrier family
A family history consistent with Lynch syndrome, such as multiple colorectal, endometrial, or other Lynch-associated cancers
Ashkenazi Jewish ancestry combined with any personal or family cancer history
After a Prostate Cancer Diagnosis
For men who have already been diagnosed with prostate cancer, (NCI, Prostate Cancer Genetics) guidelines recommend germline testing for:
High-risk or very high-risk prostate cancer (Gleason score of 8 or higher)
Any prostate cancer with a relevant family history as described above
Metastatic prostate cancer. Germline testing is recommended for all men with metastatic disease, regardless of family history
In a post-diagnosis context, germline results do two things: they inform treatment planning (some inherited mutations predict how well certain therapies will work), and they flag inherited risk implications for biological relatives. Your genetic information is private and protected, accessible only to you and your care team.
See how your genes affect your prostate cancer risk. Kadance members receive access to hereditary cancer risk testing covering 26 genes, including BRCA1, BRCA2, and Lynch syndrome genes, through a CAP-accredited, CLIA-certified laboratory.
What Does a Prostate Cancer Germline DNA Test Cover?
A hereditary prostate cancer panel typically tests for mutations in the following genes:
BRCA2: The most important hereditary prostate cancer gene. Carriers face approximately 2 to 6 times elevated lifetime prostate cancer risk, and prostate cancers in BRCA2 mutation carriers tend to be more aggressive than average.
BRCA1: Moderately elevated prostate cancer risk. Primarily known for breast and ovarian cancer associations, but clinically relevant for men as well.
Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2): Associated with moderately elevated prostate cancer risk, plus colorectal, endometrial, and other cancer risks.
HOXB13: A prostate-specific gene. The G84E variant is associated with early-onset hereditary prostate cancer.
ATM, CHEK2, PALB2: Additional cancer risk genes with growing evidence for prostate cancer association.
What Is Prostate Cancer Tumor Genomic Testing?
Tumor genomic sequencing for prostate cancer is a somatic test. It analyzes gene changes in tumor tissue, not the DNA you were born with. The clinical purpose is precision oncology: finding specific mutations in the tumor that predict how the cancer will respond to certain therapies.
Which Tumor Mutations Matter for Prostate Cancer Treatment
Several specific gene changes found through tumor genomic sequencing have direct treatment implications:
BRCA2 and BRCA1 tumor mutations: Predict response to PARP inhibitors, including olaparib and rucaparib, both of which are FDA-approved for men with BRCA-mutated metastatic prostate cancer. (NCI, Prostate Cancer Genetics)
ATM tumor mutations: May also predict PARP inhibitor response in some patients, with growing clinical evidence.
Mismatch repair deficiency (MMRd) or high microsatellite instability (MSI-H): Predicts response to pembrolizumab, an immunotherapy drug that is FDA-approved for MSI-H tumors across cancer types.
CDK12 mutations: Associated with elevated tumor mutational burden and may predict immunotherapy benefit.
Comprehensive tumor genomic panels for prostate cancer typically cover 300 to 600 genes in a single test, identifying the full range of potentially actionable mutations and resistance mechanisms.
What Do Prostate Cancer DNA Test Results Mean?
Interpreting results depends on which type of test was done:
Germline positive: An inherited harmful gene change was found. Your personal prostate cancer risk is significantly elevated. Other cancers may also be affected. For example, BRCA2 carriers also face elevated breast and pancreatic cancer risk. Biological relatives may carry the same mutation. Clinical surveillance and risk-management conversations begin with a urologist experienced in hereditary prostate cancer.
Germline negative: No harmful inherited gene change was found. Risk estimates are based on family history rather than a confirmed mutation. Family history-based surveillance recommendations may still apply.
Somatic positive (actionable mutation): A gene change was found in the tumor that may predict response to a targeted therapy. Your oncologist reviews the findings against available treatments and clinical trials.
Somatic, no actionable mutation: No currently targetable gene change was found. Treatment planning proceeds based on standard clinical parameters. Testing may be repeated if the disease progresses.
How Does DNA Testing Integrate With PSA Screening?
Germline DNA testing and PSA screening serve different purposes and are most effective when used together rather than viewed as alternatives.
PSA screening identifies current signals that may indicate prostate cancer activity. It is done repeatedly, on an ongoing basis.
Germline DNA testing identifies inherited biological risk. It is done once, and the results are relevant for life.
For men with a confirmed BRCA2 mutation or a significant family history, germline test results can directly influence PSA screening decisions, including when to start screening, how often to test, and when to pursue further evaluation. For example, screening may begin around ages 40 to 45 for BRCA2 carriers, compared with age 50 for men at average risk. In this way, germline testing can help determine whether PSA monitoring should be more intensive, a question that PSA testing alone cannot answer.
When Should Men Start PSA Screening? It Depends on Genetic Risk
Risk Profile
Start PSA At
Frequency
Why
Average risk (no family history, no known mutation)
Age 50
Per physician guidance
Standard population guideline — prostate cancer risk is not elevated above baseline
Strong family history (no confirmed mutation)
Age 40–45
Annual testing is often recommended
First-degree relative with prostate cancer before 60, or 2+ affected relatives
Confirmed BRCA2 carrier
Age 40
Annual — per NCCN
BRCA2-associated prostate cancers tend to be more aggressive; earlier and more frequent monitoring improves detection odds
Germline DNA testing results directly change when PSA monitoring should start. BRCA2 carriers begin annual PSA testing at age 40, a full decade earlier than average-risk guidelines. Source: NCCN Prostate Cancer Early Detection Guidelines.
FAQ, DNA Test for Prostate Cancer Questions
Can a DNA test detect prostate cancer?
Germline DNA testing does not detect prostate cancer. It identifies inherited genetic changes that elevate the lifetime risk of developing it. Somatic tumor genomic testing characterizes a tumor's genetic profile after a diagnosis. It does not diagnose cancer but helps guide treatment decisions for a confirmed diagnosis. There is currently no blood-based DNA test that reliably detects early prostate cancer in men without symptoms, though liquid biopsy technologies are an active area of research.
Is prostate cancer DNA testing covered by insurance?
Germline prostate cancer genetic testing is increasingly covered by health insurers when medical necessity criteria are met, particularly for men with high-risk or metastatic prostate cancer, or a significant family history. Somatic tumor genomic testing is often covered for men with advanced prostate cancer when it may inform treatment decisions. Coverage for proactive germline testing in men without a diagnosis is less consistent. Having documented family history criteria and physician involvement improves the likelihood of coverage.
What is the BRCA connection to prostate cancer?
Specific BRCA2 mutations are the most significant single inherited risk factors for hereditary prostate cancer. BRCA2 mutation carriers face approximately 2 to 6 times elevated lifetime prostate cancer risk, and associated cancers tend to be diagnosed at a younger age and have more aggressive features. Critically, BRCA2 mutations can be inherited from either parent. A man whose mother carries a BRCA2 mutation faces exactly the same elevated prostate cancer risk as one whose father carries it. This is something most men are not told. In the treatment context, BRCA2 mutations in the tumor predict response to PARP inhibitors in metastatic prostate cancer. Source: NCI.
What Your DNA Can Tell You About Prostate Cancer, Before and After a Diagnosis
Before a diagnosis, germline DNA testing tells you whether you carry an inherited gene change that significantly elevates your risk, and gives you the opportunity to start surveillance earlier, with a physician who understands what that mutation means for how intensively to monitor.
After a diagnosis, tumor genomic sequencing tells you what is driving the cancer, which targeted therapies may work against it, and which clinical trials are most relevant to your specific tumor. Together, these two tools represent the most complete use of genetic information available in prostate cancer care today.
Optimize your health. Know your genetic risk profile. Explore Kadance membership for access to hereditary cancer risk testing, genetic counseling, and a precision health approach designed for men who want more than a PSA number.
.svg)
